Literature DB >> 31933861

Expression of B7-H6 in chronic myeloid leukemia and its clinical significance.

Yanglin Cao1, Li Huo1, Ling Zhou1, Jianfeng Yang2, Zhen Weng2, Xiaofei Yang1, Jiannong Cen1, Yang He1.   

Abstract

OBJECTIVE: To examine the expression level of B7-H6 in chronic myeloid leukemia (CML) patients and to explore its clinical significance.
METHODS: Two hundred twenty-eight CML patients were included and peripheral blood (PB) and bone marrow (BM) mononuclear cells were collected for B7-H6 mRNA expression analyses by quantitative real time polymerase chain reaction (PCR).
RESULTS: The expression of B7-H6 mRNA was successfully detected in all PB and BM samples. According to the clinical characteristics of CML patients, no difference was found in the B7-H6 level of PBMCs. However, a significantly decreased B7-H6 level was noted in BM samples from CML with BCR-ABL1/ABL > 0.1% (10 copies of BCR-ABL1/10000 copies of ABL) compared to ≤ 0.1% (P < 0.0001), and a negative correlation was found between the expression level of B7-H6 in BM and the number of BCR-ABL1/ABL transcripts (r = -0.26, P = 0.0057). A significant difference in PFS was observed between patients with high expression level of B7-H6 and low expression level in BM (χ2 = 12.53, P = 0.0004).
CONCLUSION: The expression of the B7-H6 gene in CML is correlated with BCR-ABL1 copy number and responsiveness to treatment, and monitoring of B7-H6 expression may be used to predict CML prognosis, progression, and treatment efficacy evaluation. IJCEP
Copyright © 2019.

Entities:  

Keywords:  B7-H6; BCR-ABL1; Chronic myeloid leukemia; complete cytogenetic response; real-time quantitative PCR

Year:  2019        PMID: 31933861      PMCID: PMC6945099     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  21 in total

1.  Tumor Therapeutics Work as Stress Inducers to Enhance Tumor Sensitivity to Natural Killer (NK) Cell Cytolysis by Up-regulating NKp30 Ligand B7-H6.

Authors:  Guoshuai Cao; Jian Wang; Xiaodong Zheng; Haiming Wei; Zhigang Tian; Rui Sun
Journal:  J Biol Chem       Date:  2015-10-15       Impact factor: 5.157

2.  B7-H6 expression in non-small cell lung cancers.

Authors:  Xiuqin Zhang; Guangbo Zhang; Yan Qin; Ruizhen Bai; Jianan Huang
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

3.  Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.

Authors:  Andreas Hochhaus; Richard A Larson; François Guilhot; Jerald P Radich; Susan Branford; Timothy P Hughes; Michele Baccarani; Michael W Deininger; Francisco Cervantes; Satoko Fujihara; Christine-Elke Ortmann; Hans D Menssen; Hagop Kantarjian; Stephen G O'Brien; Brian J Druker
Journal:  N Engl J Med       Date:  2017-03-09       Impact factor: 91.245

Review 4.  Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program.

Authors:  J Gabert; E Beillard; V H J van der Velden; W Bi; D Grimwade; N Pallisgaard; G Barbany; G Cazzaniga; J M Cayuela; H Cavé; F Pane; J L E Aerts; D De Micheli; X Thirion; V Pradel; M González; S Viehmann; M Malec; G Saglio; J J M van Dongen
Journal:  Leukemia       Date:  2003-12       Impact factor: 11.528

5.  Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study.

Authors:  David M Ross; Susan Branford; John F Seymour; Anthony P Schwarer; Christopher Arthur; David T Yeung; Phuong Dang; Jarrad M Goyne; Cassandra Slader; Robin J Filshie; Anthony K Mills; Junia V Melo; Deborah L White; Andrew P Grigg; Timothy P Hughes
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

6.  Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions.

Authors:  Jessica Matta; Myriam Baratin; Laurent Chiche; Jean-Marie Forel; Céline Cognet; Guillemette Thomas; Catherine Farnarier; Christelle Piperoglou; Laurent Papazian; Damien Chaussabel; Sophie Ugolini; Frédéric Vély; Eric Vivier
Journal:  Blood       Date:  2013-05-17       Impact factor: 22.113

7.  Increase of bcr-abl chimeric mRNA expression in tumor cells of patients with chronic myeloid leukemia precedes disease progression.

Authors:  A Gaiger; T Henn; E Hörth; K Geissler; G Mitterbauer; T Maier-Dobersberger; H Greinix; C Mannhalter; O A Haas; K Lechner; T Lion
Journal:  Blood       Date:  1995-09-15       Impact factor: 22.113

Review 8.  Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.

Authors:  Timothy Hughes; Michael Deininger; Andreas Hochhaus; Susan Branford; Jerald Radich; Jaspal Kaeda; Michele Baccarani; Jorge Cortes; Nicholas C P Cross; Brian J Druker; Jean Gabert; David Grimwade; Rüdiger Hehlmann; Suzanne Kamel-Reid; Jeffrey H Lipton; Janina Longtine; Giovanni Martinelli; Giuseppe Saglio; Simona Soverini; Wendy Stock; John M Goldman
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

9.  The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans.

Authors:  Cameron S Brandt; Myriam Baratin; Eugene C Yi; Jacob Kennedy; Zeren Gao; Brian Fox; Betty Haldeman; Craig D Ostrander; Tomonori Kaifu; Christian Chabannon; Alessandro Moretta; Robert West; Wenfeng Xu; Eric Vivier; Steven D Levin
Journal:  J Exp Med       Date:  2009-06-15       Impact factor: 14.307

10.  Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia.

Authors:  Lisa Christiansson; Stina Söderlund; Emma Svensson; Satu Mustjoki; Mats Bengtsson; Bengt Simonsson; Ulla Olsson-Strömberg; Angelica S I Loskog
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

View more
  4 in total

1.  Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.

Authors:  Portia L Thomas; Sarah M Groves; Yun-Kai Zhang; Jia Li; Paula Gonzalez-Ericsson; Shamilene Sivagnanam; Courtney B Betts; Hua-Chang Chen; Qi Liu; Cindy Lowe; Heidi Chen; Kelli L Boyd; Prasad R Kopparapu; Yingjun Yan; Lisa M Coussens; Vito Quaranta; Darren R Tyson; Wade Iams; Christine M Lovly
Journal:  J Thorac Oncol       Date:  2021-04-08       Impact factor: 20.121

2.  B7-H6 is a new potential biomarker and therapeutic target of T-lymphoblastic lymphoma.

Authors:  Lei Yuan; Lu Sun; Siyuan Yang; Xin Chen; Jing Wang; Hongmei Jing; Yu Zhao; Xiaoyan Ke
Journal:  Ann Transl Med       Date:  2021-02

3.  B7H6 Serves as a Negative Prognostic Marker and an Immune Modulator in Human Pancreatic Cancer.

Authors:  Zheng Zhu; Kun-Yu Teng; Jian Zhou; Yunyun Xu; Lifeng Zhang; Hua Zhao; Xueguang Zhang; Lei Tian; Zhiyao Li; Ting Lu; Shoubao Ma; Zhenlong Li; Zhenyu Dai; Jing Wang; Xingyu Chen; Xing Wu; Yihan Pan; Weiqiang Shi; Zhiqun You; Hanyu Chen; Vincent Chung; Jianhua Yu; Songbing He; Xin Zhao; Lei Cao; Dechun Li
Journal:  Front Oncol       Date:  2022-03-03       Impact factor: 6.244

4.  B7-H6 as an efficient target for T cell-induced cytotoxicity in haematologic malignant cells.

Authors:  Xin Sun; Jingyuan Zhao; Li Ma; Ximing Sun; Jing Ge; Yang Yu; Juan Ma; Man Zhang
Journal:  Invest New Drugs       Date:  2020-08-07       Impact factor: 3.850

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.